Adocia : Plusieurs catalyseurs à court terme
>Une visibilité financière jusqu’à fin août - Adocia publie son chiffre d’affaires et sa trésorerie au titre du quatrième trimestre 2023. La société ne réalise pas encore de ventes et la topline est principalement composée de revenus entrant dans le cadre de ses partenariats. Celle-ci s’élève à 0.2 M€ (vs 1.7 M€ au T4 2022) représentant les prestations facturées à son partenaire Dongbao dans le cadre des trois essais cliniques en Europe de BC Combo. La trésorerie à f...ADOCIA is a biotechnology company based in France. Co. specializes in the development of formulations for already-approved therapeutic proteins with a primary focus on insulins and treatments for diabetic foot ulcers. Co.'s biotherapy products are used in tissue regeneration and for treating chronic diseases. Co.'s proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins in areas such as wound Healing, diabetes, ulcers and monoclonal antibody creation. Co. also maintains activities in the formulation of monoclonal antibodies for the treatment of various chronic pathologies (oncology, inflammation, etc.).
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.